Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO® (pitavastatin) and Protease Inhibitor Combination (darunavir/ritonavir) in Healthy Volunteers

WASHINGTON, July 22, 2012 /PRNewswire/ — Kowa Pharmaceuticals America, Inc. (Kowa Pharmaceuticals) and Eli Lilly and Company (Lilly) (NYSE: LLY) today released results from a pharmacokinetic (PK) study exploring potential drug interaction between the cholesterol medication pitavastatin (LIVALO) 4 m

On 07.22.12 , In Uncategorized , by

PR Newswire: News for Investors

Visit Authors Website  |  All Articles From This Author
If you enjoyed this article, please consider sharing it!
Icon Icon Icon

Ad

Ad

Ad

Find Us on Facebook